Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 12/20 | 0.70 |
| ▸ | HSP90B1 | P14625 | 9/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23202316 | 0.86 | TRAP1 (0.69) | TRAP1HSP90B1HSP90AA1TLR7ADORA2A | |
| SCHEMBL30012102 | 0.86 | TRAP1 (0.69) | TRAP1HSP90B1HSP90AA1TLR7ADORA2A | |
| SCHEMBL872739 | 0.80 | PDE5A (0.47) | TRAP1HSP90B1HSP90AA1ADORA2AKDM4E | |
| SCHEMBL14366720 | 0.78 | HSP90AA1 (0.62) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL4268613 | 0.77 | HSP90AA1 (0.64) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL14366715 | 0.77 | HSP90AA1 (0.57) | TRAP1HSP90B1HSP90AA1ADORA2A | |
| SCHEMBL14366723 | 0.76 | TRAP1 (0.56) | TRAP1HSP90B1HSP90AA1 | |
| SCHEMBL30012779 | 0.76 | TLR7 (0.62) | TRAP1HSP90B1TLR7ADORA2AKDM4E | |
| SCHEMBL23392757 | 0.76 | TLR7 (0.62) | TRAP1HSP90B1TLR7ADORA2AKDM4E | |
| SCHEMBL14366714 | 0.75 | HSP90AA1 (0.55) | TRAP1HSP90B1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| EP-2619211-B1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006177-B2 | Fused tricyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| EP-2619211-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Private Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038980-A2 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252885-A1 | FUSED TRICYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA2B, ADORA1 | TRAP1 1113/4885HSP90B1 3263/4885HSP90AA1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.